After confirming that erlotinib affects cognitive function, tau pathology, and astrogliosis in 3-month-old and 6-month-old PS19 mice, we examined the impact of erlotinib on cognitive function in another model of AD, 5xFAD mice, which overexpress Aβ. This evidence concerns the gene MAPT and Alzheimer disease.